RPRX Stock Analysis
RP
Neutral
Based on Eyestock quantitative analysis, RPRX`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Undervalued
Market cap $B
12.655
Dividend yield
3.76 %
Shares outstanding
443.17 B
Royalty Pharma Plc provides drug development services. The company is headquartered in New York City, New York and currently employs 75 full-time employees. The company went IPO on 2020-06-16. The firm collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on more than 35 commercial products, including Vertexs Trikafta, Kalydeco, Orkambi and Symdeko, Biogens Tysabri, AbbVie and Johnson & Johnsons Imbruvica, Astellas and Pfizer's Xtandi, GSKs Trelegy, Novartis Promacta, Pfizer's Nurtec ODT, Johnson & Johnsons Tremfya, Roches Evrysdi, Gilead's Trodelvy, and 12 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Olpasiran, Omecamtiv mecarbil, Pelabresib, Pelacarsen, Seltorexant, Trontinemab, Tulmimetostat and Zavegepant. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.